Antibody discovery specialist AbCellera Biologics Inc (Nasdaq:ABCL) announced on Wednesday that it has expanded its existing collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to discover therapeutic antibodies for immunology, cardiovascular disease and neuroscience.
The expanded agreement builds on a successful partnership established in 2020, which included eight programmes and an exclusive licence to AbCellera's COVID-19 antibody programme.
Lilly has the right to develop and commercialise antibodies resulting from the collaboration. AbCellera will receive upfront and research payments, as well as potential milestone payments and royalties.
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
Bayer launches Phase II study for chronic kidney disease treatment
AstraZeneca's Calquence combo improves 1L CLL progression-free survival
Destiny Pharma's XF-73 nasal gel reduces antibiotic use in cardiac surgery patients